Search
Descriptor English: Isocarboxazid
Descriptor Spanish: Isocarboxazida
Descriptor isocarboxacida
Entry term(s) isocarboxazida
Scope note: Inhibidor de la MAO que es efecivo en el tratamiento de la depresión endógena, trastornos distímicos y depresiones atípicas. Asimismo, es útil en el tratamiento de episodios de pánico y trastornos fóbicos. (AMA, Drug Evaluations Annual, 1994, p311)
Descriptor Portuguese: Isocarboxazida
Descriptor French: Isocarboxazide
Tree number(s): D03.383.129.385.300
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D007520
Scope note: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antidepressive Agents
Monoamine Oxidase Inhibitors
Registry Number: 34237V843T
CAS Type 1 Name: 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide
DeCS ID: 7687
Unique ID: D007520
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1966/01/01
Date of Entry: 1999/01/01
Revision Date: 2016/05/31
Isocarboxazid - Preferred
Concept UI M0011750
Scope note An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)
Preferred term Isocarboxazid



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey